Bellerophon Therapeutics (NASDAQ:BLPH) Receives New Coverage from Analysts at StockNews.com
Bellerophon Therapeutics (NASDAQ:BLPH) Receives New Coverage from Analysts at StockNews.com
StockNews.com began coverage on shares of Bellerophon Therapeutics (NASDAQ:BLPH – Get Rating) in a report published on Saturday morning. The brokerage issued a sell rating on the biotechnology company's stock.
斯托克新闻网在周六上午发布的一份报告中开始报道贝勒罗芬治疗公司(纳斯达克：BLPH-GET Rating)的股票。该经纪公司对这家生物技术公司的股票发布了卖出评级。
Other analysts have also issued research reports about the company. Brookline Capital Acquisition decreased their price target on Bellerophon Therapeutics from $26.00 to $19.00 in a research note on Monday, April 4th. Brookline Capital Management decreased their price target on Bellerophon Therapeutics from $26.00 to $19.00 in a research note on Monday, April 4th.
其他分析师也发布了关于该公司的研究报告。Brookline Capital Acquisition在4月4日星期一的一份研究报告中将他们对贝勒罗芬治疗公司的目标价从26.00美元下调至19.00美元。Brookline资本管理公司在4月4日星期一的一份研究报告中将他们对贝勒罗芬治疗公司的目标价从26.00美元下调至19.00美元。
Bellerophon Therapeutics Stock Performance
贝勒罗芬治疗公司股票表现
BLPH opened at $1.28 on Friday. Bellerophon Therapeutics has a 1 year low of $0.67 and a 1 year high of $4.98. The stock's 50 day simple moving average is $1.05 and its 200-day simple moving average is $1.83.
BLPH上周五开盘报1.28美元。贝勒罗芬治疗公司的一年低点为0.67美元，一年高位为4.98美元。该股的50日简单移动均线切入位为1.05美元，200日简单移动均线切入位为1.83美元。
About Bellerophon Therapeutics
关于贝勒罗芬治疗公司
(Get Rating)
(获取评级)
Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its product includes INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.
贝勒罗芬治疗公司是一家临床阶段治疗公司，专注于在美国开发治疗心肺疾病的产品。其产品包括INOPulse，这是一种用于治疗肺动脉高压的专有脉冲式一氧化氮输送平台。
See Also
另请参阅
- Get a free copy of the StockNews.com research report on Bellerophon Therapeutics (BLPH)
- MarketBeat: Week in Review 7/11 – 7/15
- Should You Have These Two Banks In Your Portfolio?
- Is Coupang's Stock On The Verge Of A Turnaround?
- Why Shopify Stock Split...And is as Shoppable as Ever
- Verint Systems Stock is a Customer Engagement Play
- 免费获取StockNews.com关于贝勒罗芬治疗(BLPH)的研究报告
- MarketBeat：回顾一周7/11-7/15
- 你的投资组合中应该有这两家银行吗？
- Coupang的股票即将翻身吗？
- 为什么Shopify股票拆分...并一如既往地适合购物
- Verint Systems Stock是一场客户互动活动
Receive News & Ratings for Bellerophon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受贝勒罗芬治疗日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Bellerophon治疗公司和相关公司的最新新闻和分析师评级的每日简要摘要。